Proprietary AI analyst is now available

Promopharm Valuation Multiples

Discover revenue and EBITDA valuation multiples for Promopharm and similar public comparables like Vita Life Sciences, Venture Life Group, FitLife Brands, Hyundai Bioland Co and more.

Promopharm Overview

About Promopharm

Promotion Pharmaceutique du Maghreb is engaged in production, marketing, import and export of pharmaceuticals, parapharmaceuticals, dermopharmaceuticals and cosmetics.


Founded

1985

HQ

Morocco

Employees

N/A

Financials (FY)

Revenue: $104M
EBITDA: $12M

EV

$91M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Promopharm Financials

Promopharm reported last fiscal year revenue of $104M and EBITDA of $12M.

In the same fiscal year, Promopharm generated $45M in gross profit, $12M in EBITDA, and $6M in net income.


Promopharm P&L

In the most recent fiscal year, Promopharm reported revenue of $104M and EBITDA of $12M.

Promopharm is profitable as of last fiscal year, with gross margin of 43%, EBITDA margin of 12%, and net margin of 6%.

See analyst estimates for Promopharm
Last FY202320242025202620272028
Revenue$104M$86M$95M$104M
Gross Profit$45M$38M$41M$45M
Gross Margin43%45%43%43%
EBITDA$12M$10M$12M$12M
EBITDA Margin12%11%12%12%
EBIT Margin9%13%11%9%
Net Profit$6M$6M$6M$6M
Net Margin6%7%6%6%

Financial data powered by Morningstar, Inc.

Promopharm Stock Performance

Promopharm has current market cap of $90M, and enterprise value of $91M.

EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$91M$90M-----

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Promopharm Valuation Multiples

Promopharm trades at 0.9x EV/Revenue multiple, and 7.4x EV/EBITDA.

See NTM and 2027E valuation multiples for Promopharm

Promopharm Financial Valuation Multiples

As of June 26, 2026, Promopharm has market cap of $90M and EV of $91M.

Promopharm has a P/E ratio of 14.2x.

Last FY202320242025202620272028
EV/Revenue0.9x1.1x0.9x0.9x
EV/EBITDA7.4x9.2x7.8x7.4x
EV/EBIT9.9x8.4x8.8x9.9x
EV/Gross Profit2.0x2.4x2.2x2.0x
P/E14.2x14.9x15.4x14.2x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Promopharm Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Promopharm Margins & Growth Rates

In the most recent fiscal year, Promopharm reported gross margin of 43%, EBITDA margin of 12%, and net margin of 6%.

See estimated margins and future growth rates for Promopharm

Promopharm Margins

Last FY20242025202720282029
Gross Margin43%43%43%
EBITDA Margin12%12%12%
EBIT Margin9%11%9%
Net Margin6%6%6%

Promopharm Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth12%9%
Gross Profit Growth9%9%
EBITDA Growth19%5%
EBIT Growth(5%)(10%)
Net Profit Growth(3%)9%

Data powered by FactSet, Inc. and Morningstar, Inc.

Promopharm Operational KPIs

Access forward-looking KPIs for Promopharm
Last FY202320242025202620272028
Opex to Revenue35%32%33%35%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Promopharm Competitors

Promopharm competitors include Vita Life Sciences, Venture Life Group, FitLife Brands, Hyundai Bioland Co, Chong Kun Dang Holdings, Enzymatica, Hofseth BioCare, Provexis, Biome Australia and Valbiotis.

Most Promopharm public comparables operate across Nutraceuticals & Cosmeceuticals.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Vita Life Sciences1.1x-6.5x-
Venture Life Group1.8x1.3x10.9x7.4x
FitLife Brands1.9x1.6x10.8x10.3x
Hyundai Bioland Co0.7x-5.0x-
Chong Kun Dang Holdings0.6x-4.7x-
Enzymatica9.1x9.1x(11.5x)-
Hofseth BioCare3.2x-(11.2x)-
Provexis22.3x-(63.7x)-

This data is available for Pro users. Sign up to see all Promopharm competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Promopharm

When was Promopharm founded?Promopharm was founded in 1985.
Where is Promopharm headquartered?Promopharm is headquartered in Morocco.
Is Promopharm publicly listed?Yes, Promopharm is a public company listed on Casablanca Stock Exchange.
What is the stock symbol of Promopharm?Promopharm trades under PRO ticker.
When did Promopharm go public?Promopharm went public in 2007.
Who are competitors of Promopharm?Promopharm main competitors include Vita Life Sciences, Venture Life Group, FitLife Brands, Hyundai Bioland Co, Chong Kun Dang Holdings, Enzymatica, Hofseth BioCare, Provexis, Biome Australia, Valbiotis.
What is the current market cap of Promopharm?Promopharm's current market cap is $90M.
What is the current revenue of Promopharm?Promopharm's last fiscal year revenue is $104M.
What is the current EV/Revenue multiple of Promopharm?Current revenue multiple of Promopharm is 0.9x.
Is Promopharm profitable?No, Promopharm is not profitable.
How many companies Promopharm has acquired to date?Promopharm hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Promopharm has invested to date?Promopharm hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Promopharm

Lists including Promopharm

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial